x min read

Hot Alert: SeaDrill Limited (NYSE:SDRL), Argos Therapeutics, Inc. (NASDAQ:ARGS), Monotype Imaging Holdings Inc. (NASDAQ:TYPE), Actavis plc (NYSE:ACT), Ardelyx, Inc. (NASDAQ:ARDX)

Hot Alert: SeaDrill Limited (NYSE:SDRL), Argos Therapeutics, Inc. (NASDAQ:ARGS), Monotype Imaging Holdings Inc. (NASDAQ:TYPE), Actavis plc (NYSE:ACT), Ardelyx, Inc. (NASDAQ:ARDX)
Written by
Charles Donlon
Published on
November 6, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

SeaDrill Limited (NYSE:SDRL) announced that it has entered into an agreement with Seadrill Partners pursuant to which the Company will sell to Seadrill Capricorn Holdings LLC, Seadrill Partners' 51% owned subsidiary ("Capricorn Holdings"), all of the ownership interests in the entities that own and operate the drillship, the West Vela (the "Vela Acquisition"). The Vela Acquisition, which is expected to close within 3 days, will be accomplished through a series of purchases, contributions and assumption of debt. SeaDrill Limited (NYSE:SDRL) belongs to Basic Materials sector. Its net profit margin is 80.60% and weekly performance is -7.25%. On last trading day company shares ended up $21.23. SeaDrill Limited (NYSE:SDRL) distance from 50-day simple moving average (SMA50) is -23.08%. Invetech, and contract manufacturing, Argos Therapeutics, Inc. (NASDAQ:ARGS) announced that they have entered into an agreement under which Invetech will develop and supply manufacturing systems to support production needs for fully personalized immunotherapies based on Argos' Arcelis® technology platform. Under the terms of the agreement, Invetech will provide Argos with services, technology and equipment to support the design, development, supply and maintenance of customized manufacturing systems to support production of patient-specific immunotherapies. Argos Therapeutics, Inc. (NASDAQ:ARGS) shares remains unchanged in last trading session and ended the day at $9.99. ARGS return on assets is -79.70%. Argos Therapeutics, Inc. (NASDAQ:ARGS) quarterly performance is 64.31%. On Oct 31. Monotype Imaging Holdings Inc. (NASDAQ:TYPE) announced financial results for the third quarter ended Sept. 30, 2014. Revenue was $47.1 million, up 16 percent compared to $40.5 million for the third quarter of 2013. Creative Professional revenue was $20.1 million, a 22 percent increase over the same period in 2013. OEM revenue was $26.9 million, a 12 percent increase from the third quarter of 2013.On 05 November, Monotype Imaging Holdings Inc. (NASDAQ:TYPE) shares advanced 0.89% and was closed at $28.36. TYPE EPS growth in last 5 year was 12.60%. Monotype Imaging Holdings Inc. (NASDAQ:TYPE) year to date (YTD) performance is -10.25%. Specialty pharmaceutical company Actavis plc (NYSE:ACT) reported a loss for the third quarter as higher revenues resulting from the company's recent acquisitions were offset by a surge in expenses. Actavis plc (NYSE:ACT) belongs to Healthcare sector. Its net profit margin is 0.60% and weekly performance is 3.82%. On last trading day company shares ended up $247.91. Actavis plc (NYSE:ACT) distance from 50-day simple moving average (SMA50) is 5.18%.On Oct. 23, Ardelyx, Inc. (NASDAQ:ARDX) announced that Ardelyx, together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will present tenapanor-related preclinical and clinical results during Kidney Week 2014, the annual meeting of the American Society of Nephrology (ASN). Ardelyx, Inc. (NASDAQ:ARDX) shares advanced 3.21% in last trading session and ended the day at $23.14. ARDX return on assets is -19.30%. Ardelyx, Inc. (NASDAQ:ARDX) quarterly performance is 92.35%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.